Business
AI summaryPoxel S.A. is a clinical-stage biopharmaceutical company developing treatments for metabolic conditions, type 2 diabetes, and liver diseases, including rare metabolic disorders. Its lead product, TWYMEEG (Imeglimin), is an oral drug approved for type 2 diabetes in Japan, while PXL770 and PXL065 are being studied for chronic metabolic conditions such as non-alcoholic steatohepatitis. The company holds licensing agreements with Enyo Pharma, DeuteRx, and Sumitomo Pharma. Poxel was incorporated in 2009 and is headquartered in Lyon, France.
